We are live on ! Find out more
PACB icon

Pacific Biosciences
PACB

160 hedge funds and large institutions have $873M invested in Pacific Biosciences in 2019 Q1 according to their latest regulatory filings, with 29 funds opening new positions, 65 increasing their positions, 41 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

59% more repeat investments, than reductions

Existing positions increased: 65 | Existing positions reduced: 41

33% more funds holding in top 10

Funds holding in top 10: 3 → 4 (+1)

26% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 23

8% more capital invested

Capital invested by funds: $809M → $873M (+$63.2M)

6.85% more ownership

Funds ownership: 73.1% → 79.95% (+6.9%)

3% more funds holding

Funds holding: 155 → 160 (+5)

73% less call options, than puts

Call options by funds: $1.19M | Put options by funds: $4.36M

Holders
160
Holders Change
+5
Holders Change %
+3.23%
% of All Funds
3.46%
Holding in Top 10
4
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+33.33%
% of All Funds
0.09%
New
29
Increased
65
Reduced
41
Closed
23
Calls
$1.19M
Puts
$4.36M
Net Calls
-$3.17M
Net Calls Change
-$7.29M

Top Buyers

1
UOC
UBS O'Connor
Illinois
+$22.2M
2
Citadel Advisors
Citadel Advisors
Florida
+$19M
3
KLCMU
Kite Lake Capital Management (UK)
United Kingdom
+$18.7M
4
WIC
Water Island Capital
New York
+$16.3M
5
VI
Versor Investments
New York
+$15.2M

Top Sellers

1
CCM
Consonance Capital Management
New York
-$18.2M
2
Alyeska Investment Group
Alyeska Investment Group
Illinois
-$18M
3
Capital International Investors
Capital International Investors
California
-$15.4M
4
OIM
Oracle Investment Management
Connecticut
-$10.5M
5
MF
Magnetar Financial
Illinois
-$7.7M
Name Holding Trade Value Shares
Change 		Change in
Stake
RhumbLine Advisers
76
RhumbLine Advisers
Massachusetts
$1.3M +$38.8K +5,364 +3%
KPF
77
K2 Principal Fund
Ontario, Canada
$1.17M +$1.17M +161,697 New
FFH
78
Fairfax Financial Holdings
Ontario, Canada
$1.16M – – –
JG
79
Jefferies Group
New York
$1.07M +$527K +72,813 +96%
ACPU
80
Arrowgrass Capital Partners (US)
Delaware
$1.03M -$347K -47,949 -25%
BF
81
BOK Financial
Oklahoma
$1.01M +$685K +94,719 +209%
TI
82
TT International
United Kingdom
$976K +$976K +135,000 New
PG
83
Pendal Group
Australia
$955K – – –
GH
84
GAM Holding
Switzerland
$915K -$333K -46,000 -27%
New York State Common Retirement Fund
85
New York State Common Retirement Fund
New York
$889K – – –
MSAM
86
Moloney Securities Asset Management
Missouri
$881K -$470K -65,034 -35%
CI
87
Cowen Inc
New York
$869K +$149K +20,540 +21%
Bank of America
88
Bank of America
North Carolina
$801K +$288K +39,884 +56%
EAM
89
Exane Asset Management
France
$714K +$714K +98,743 New
AGM
90
Alpine Global Management
New York
$710K +$710K +98,220 New
PAMP
91
Polar Asset Management Partners
Ontario, Canada
$687K +$687K +95,000 New
TMAM
92
Tokio Marine Asset Management
Japan
$675K +$675K +93,300 New
Wells Fargo
93
Wells Fargo
California
$655K +$50.2K +6,947 +8%
Manulife (Manufacturers Life Insurance)
94
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$650K +$66K +9,126 +11%
AIG
95
American International Group
New York
$637K -$14.1K -1,946 -2%
UBS AM
96
UBS AM
Illinois
$612K +$84.4K +11,674 +16%
DCM
97
Dupont Capital Management
Delaware
$610K +$610K +84,403 New
LOAMU
98
Lombard Odier Asset Management (USA)
New York
$578K -$289K -40,000 -33%
NSEDCP
99
NJ State Employees Deferred Compensation Plan
New Jersey
$578K +$217K +30,000 +60%
ACA
100
Atlas Capital Advisors
Wyoming
$535K – – –
2 3
4
5 6

PACB Hedge Fund Activity: Q1 2019 in Review

160 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Pacific Biosciences (PACB) for Q1 2019, worth a combined $873M — up 7.8% from $809M a quarter earlier.

Buyers outnumbered sellers: 29 funds opened new PACB positions and 23 closed out — a net gain of 6 holders — while 65 added to existing stakes and 41 trimmed.

The largest buyer was UBS O'Connor, adding an estimated $22.2M. The largest seller was Consonance Capital Management, exiting entirely with an estimated $18.2M sold.

  • 160 institutional investors held Pacific Biosciences (PACB) as of Q1 2019, up from 155 in Q4 2018.
  • Funds reported $873M of Pacific Biosciences stock for Q1 2019, up 7.8% quarter-over-quarter.
  • 29 funds opened new Pacific Biosciences positions in Q1 2019 and 23 closed out, a net change of +6 holders.
  • The largest Pacific Biosciences buyer in Q1 2019 was UBS O'Connor, an estimated $22.2M added.
  • The largest Pacific Biosciences seller in Q1 2019 was Consonance Capital Management, an estimated $18.2M sold.

Based on aggregated 13F filings for Q1 2019.